Key result
Intracellular DNA sensing and downstream signaling pathways contribute to the pathogenesis of autoinflammatory and systemic rheumatic diseases, providing potential targets for novel therapies.
Why the study?
Evidence that endogenous DNA and DNA sensing drive autoinflammatory diseases prompted the question of whether endogenous DNA can also induce inflammation in human autoimmune diseases.
This review highlights the role of intracellular DNA sensing in driving autoinflammatory and autoimmune diseases, providing insights for developing targeted therapies.
May prompt genetic testing in unexplained periodic inflammation; leaves open targeted therapies against endogenous DNA sensing.
Evidence has shown that DNA is a pathogen-associated molecular pattern, posing a unique challenge in the discrimination between endogenous and foreign DNA. This challenge is highlighted by certain autoinflammatory diseases that arise from monogenic mutations and result in periodic flares of inflammation, typically in the absence of autoantibodies or antigen-specific T lymphocytes. Several autoinflammatory diseases arise due to mutations in genes that normally prevent the accrual of endogenous DNA or are due to mutations that cause activation of intracellular DNA-sensing pathway components. Evidence from genetically modified murine models further support an ability of endogenous DNA and DNA sensing to drive disease pathogenesis, prompting the question of whether endogenous DNA can also induce inflammation in human autoimmune diseases. In this review, we discuss the current understanding of intracellular DNA sensing and downstream signaling pathways as they pertain to autoinflammatory disease, including the development of monogenic disorders such as Stimulator of interferon genes-associated vasculopathy with onset in infancy and Aicardi-Goutières syndrome. In addition, we discuss systemic rheumatic diseases, including certain forms of systemic lupus erythematosus, familial chilblain lupus, and other diseases with established links to intracellular DNA-sensing pathways, and highlight the lessons learned from these examples as they apply to the development of therapies targeting these pathways.
No takes yet. Share an insight, caveat, or question.
MacLauchlan et al. (2022) conducted a review in Autoinflammatory and autoimmune diseases. Intracellular DNA sensing was evaluated. Intracellular DNA sensing and downstream signaling pathways contribute to the pathogenesis of autoinflammatory and systemic rheumatic diseases, providing potential targets for novel therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: